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Background: Men with a negative first prostate biopsy will undergo one or more additional biopsies if they remain
at high suspicion of prostate cancer. To date, there are no diagnostic tests capable of identifying patients at risk for
a positive diagnosis with the predictive power needed to eliminate unnecessary repeat biopsies. Efforts to develop
clinical tests using the epigenetic signature of cores recovered from first biopsies have been limited to a few
markers and lack the sensitivity and specificity needed for widespread clinical adoption.
Methods: We developed methylation-specific quantitative polymerase chain reaction assays for a panel of 24
markers that are preferentially methylated in prostate cancer. We modified the bisulfite conversion conditions to
allow the integration of the methylation information from multiple markers. We determined the methylation status
of the 24 markers in 213 prostate biopsy cores from 104 patients, 37 prostate cancer patients and 67 controls. We
performed logistic regression on combinations of markers as well as the entire panel of 24 markers to identify the
best candidates for a diagnostic test.
Results: The marker panel differentiated between cancer cores and benign cores from non-cancer patients with
100% sensitivity and 97% specificity. Furthermore, the panel detected significant methylation in benign cores from
prostate cancer patients that was not present in controls. Using methylation of 5 out of 24 to define a cancer case,
the analysis of a single benign biopsy core identified 62% of prostate cancer patients undergoing repeat biopsies.
ROC curve analysis showed that markers commonly methylated in benign cores from cancer patients are the
best candidates for a diagnostic test. The results suggest that 5 to 10 markers will be needed to achieve optimal
predictive power.
Conclusions: This study shows that epigenetic field effects differ significantly between cancer patients and
controls. Their detection in benign biopsy cores can form the basis of diagnostic tests to identify patients in need
of repeat biopsies, reducing the cost of continued PCA screening by up to 40%. They could also be used to identify
prostate cancer patients with low grade disease who are likely candidates for active surveillance or focal therapy.
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For over 2 decades, the prostate specific antigen test
(PSA) has been used to screen for prostate cancer (PCA)
with controversial outcomes [1-3]. Studies have shown
that there is no PSA cutoff that would simultaneously
optimize the sensitivity and specificity [4-8]. Lowering
the PSA cutoff improves the sensitivity but drastically in-
creases the number of unnecessary biopsies, particularly
for patients with PSA levels below 10 ng/ml.
Prostate biopsies remain the gold standard for PCA
diagnosis. With a sensitivity of about 70%, they miss
about one third of cancers because they only sample 1%
of the prostate gland [9-11]. Therefore, a negative first
biopsy can ? t rule out the presence of cancer. Patients at
high suspicion of cancer following a first negative biopsy
present a challenge to the treating physician who needs
to balance the morbidity associated with repeat biopsies
with the risk of missing what might be a significant can-
cer [12-14]. Cancers detected on first re-biopsy are not
necessarily lower grade or stage which makes a repeat
biopsy the safest clinical option [15,16]. Despite years of
research, we still lack diagnostic methods capable of
identifying patients with a negative first biopsy who are
in need of a repeat biopsy with the sensitivity and speci-
ficity needed to spare non cancer patients the burden of
repeat biopsies.
The detection of abnormal genetic and epigenetic
fields associated with cancer in benign biopsy cores or
circulating DNA could serve as a diagnostic tool to iden-
tify patients in need of repeat biopsies. Their presence
has been inferred from variations in gene expression and
protein levels, from somatic mutations, deletions, and
DNA methylation [17-28]. The PCA3 urine test, which
measures the expression levels of a prostate specific gene
in cells recovered following a digital rectal exam (DRE),
differentiated cancer patients from controls with 77%
sensitivity and 57% specificity [29,30]. Several studies
have shown that the gene expression profile of tumor-
associated benign tissues differs significantly from be-
nign tissue obtained from tumor free donors [17-19].
The analysis of negative first biopsies for the presence of
a deletion in the mitochondrial genome identified pa-
tients in need of repeat biopsies with 84% sensitivity and
54% specificity [22]. None of the tests available today
achieved the clinical utility needed to justify the cost of
screening. Technical assessments by insurance providers
also find insufficient evidence to support the use of
gene-based tests for PCA diagnostics [31-33].
Epigenetic field effects in histologically normal tissues
of cancerous prostates are well documented [23-28]. The
MATLOC study showed that the number of unnecessary
repeat biopsies can be reduced by analyzing benign cores
for the methylation of 3 CpG islands commonly methyl-
ated in prostate cancer [28]. Similar to gene-based tests,studies of epigenetic biomarkers did not achieve the sen-
sitivity and specificity needed for widespread clinical
adoption. We undertook this study to identify additional
epigenetic markers capable of accurately differentiating
between pathologically benign and cancerous prostate
tissues. We selected 19 additional markers: ADCY4,
ARHGEF10, CXCL14, CYBA, GFRA2, GPX7, GRASP,
HAPLN3, HEMK1, HOXB5, HOXD9, KIFC2, KLK10,
LOXL2, MOXD1, NEUROG3, RASSF5, SLC16A5, and
SOCS3 (as described in Materials and Methods). We
included GSTP1, APC, PTGS2, RARB, and RASSF1 to
facilitate comparison of our results to published re-
ports. We analyzed the methylation of the entire panel
in DNA recovered from cancer, abnormal and benign
biopsy tissues obtained from patients undergoing re-
peat biopsies. The data shows that the methylation of
benign tissues differs significantly between cancer patients
and controls. Methylation is minimal in benign tissues
from controls and extensive in both benign and cancer
cores from cancer patients. The differential methylation of
benign prostatic tissues can be exploited to improve PCA
diagnostics. It can serve as the basis for a diagnostic test
aimed at eliminating unnecessary biopsies which will likely
require 5 to 10 markers to achieve the predictive power
needed for clinical adoption. It may also be useful in the
selection of patients who are likely candidates for watchful
waiting or focal therapy. The number of methylated be-
nign cores and the extent of their methylation will likely
have additional diagnostic value as markers for high grade
disease and poor prognosis.
Results
Patient characteristics
One hundred and four patients (67 controls and 37
cases) were enrolled in this retrospective study. Patient
characteristics are shown in Table 1. Ninety patients
underwent multiple biopsies including 66 out of 67 con-
trols. Patients ranged in age between 49 and 86 years
old. Patients with elevated PSA were considered controls
if they underwent repeat biopsies and have not yet been
diagnosed with prostate cancer. The follow-up time
ranged from 19 to 64 months. None of the controls
underwent an additional biopsy at the end of the study
to rule out the presence of prostate cancer. They only
received routine care.
On average, 2 biopsy cores were obtained per patient.
For controls, we analyzed 2 histologically benign cores
or 1 benign and 1 abnormal core (high grade prostatic
intraepithelial lesions (HGPIN) or atypical small acinar
proliferation (ASAP)) when available. For cancer cases,
one of the 2 cores was the cancer core and the second
core was either benign or abnormal. The volume of can-
cer was estimated by the pathologist based on 2 H&E
stained sections which flanked the 5 sections used for
Table 1 Patient characteristics and available tissues
a. Prostate biopsy cores
Characteristic Controls
(N = 67)
Cases (N = 37)
Age (yrs) 63.66
(8.1, N = 67)
70.9 (9.0, N = 31)
Race
Black 3 (4.5%) 1 (2.7%)
Hispanic 0 (0%) 0 (0%)
White 64 (95.5%) 19 (51.4%)
Unknown 0 (0%) 17 (45.9%)
Number cores available
1 10 (14.9%) 0 (0%)
2 56 (83.5%) 28 (75.7%)
3 1 (1.5%) 4 (10.8%)
4 0 (0%) 5 (13.5%)
Total 125 88
Number benign cores available
1 25 (37.3%) 29 (78.4%)
2 41 (61.2%) 2 (5.4%)
3 0 (0%) 1 (2.7%)
Number abnormal cores
available
1 17 (25.4%) 7 (18.9%)
2 0 (0%) 3(8.1%)
3 1 (1.5%) 0 (0%)
Number cancer cores available
1 0 (0%) 35 (94.6%)








Age (n = 67) 63.33 63.66 8.11 49.17-86.08
PSA (n = 66) 6.22 7.3 4.651 0.09-23.31
Follow Up In Mos.
(n = 67)
53 50.46 10.656 19-66
Cases
Age (n = 31) 72.17 70.77 9.025 52.33-84.33
PSA (n = 29) 5.9 6.45 2.28 2.9-12
Case Gleason Score
(n = 29)
7 7.1 0.938 6-9
Core Gleason Score
(n = 38)
6 6.53 1.269 4-9
% Core Involved
(n = 38)
20 23.73 18.995 <1-80
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to 80% with a median of 20 and a mean of 25% (SD
18.995). The sections we received from one case weredevoid of cancer but ASAP was present. For the purpose
of this study, we classified the core as cancer because
the sections were derived from within 10 microns of the
pathologically visible cancer. This core exhibited methy-
lation at 9 markers.
Quantitative MS-PCR assay optimization
For this study, we selected 19 novel markers with methyla-
tion frequencies in PCA ranging between 50 and 90% and
developed semi-quantitative MS-qPCR assays suitable for
the analysis of formalin-fixed paraffin-embedded biopsy
tissues. Marker selection and a list of CpG islands and
assay conditions are described in the Additional file 1.
Genereux et al. showed that bisulfite conversion of
methylated cytosines accrue on DNA templates mostly
after all unmethylated cytosines have been converted to
uracil [34]. To minimize failed conversions of unmethy-
lated cytosines and reduce the false positive error rate,
we introduced in vitro methylation at AluI (AGCT) and
HaeIII (GGCC) sites on all templates prior to deamin-
ation. The in vitro methylation resulted in methylated
cytosines at known locations in every DNA fragment
which was expected to drive the preferential deamin-
ation of unmethylated cytosines.
In DNA methylation studies, the use of a reference
gene to estimate the degree of deamination of a se-
quence of interest is commonly accepted even though
there is no experimental evidence to suggest that all
DNA sequences deaminate or degrade at the same rate.
The use of a reference gene is valid only if it deaminated
and degraded at the same rate as the sequence of
interest. During assay optimization, we observed that
markers deaminated and degraded at different rates that
were dependent on DNA concentration. We could not
use a single reference sequence to estimate the degree of
deamination of all 24 markers. Instead, we determined
using cancer cell line DNAs, the optimal length of bisul-
fite treatment for each marker and selected conditions
that resulted in no detectable amplification from nega-
tive controls (lymphoblastoid DNAs and some of the
cancer cell lines) and a robust amplification from posi-
tive controls (prostate cancer cell lines and fully methyl-
ated CCL119 DNA). This approach yields data that is
not dependent on reference genes or clinical information
for accuracy and is more suitable for the analytical valid-
ation methods required for diagnostic tests. It allows for
absolute marker quantitation independent of reference
genes. It also allows for the empirical determination of
the range of DNA concentrations suitable for analysis
under a given bisulfite conversion protocol and the limit
of detection of individual marker.
For each MS-qPCR assay, we determined using con-
trol DNAs, the analytical sensitivity and specificity for
increasing amounts of cancer cell line DNAs (from
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centrations suitable for deamination under the selected
conditions. All markers were detectable from the 2.5 ng
bisulfite reactions from at least 1 cancer cell line corre-
sponding to an input of about 100 copies pre-bisulfite
per multiplex PCR reaction. We used a single cutoff of
35 cycles for all MS-qPCR assays. Any sample yielding
an amplification signal for any marker below 35 cycles
was considered methylated at that marker. For markers
RASSF5, MOXD1, KIFC2, NEUROG3, and HEMK1, two
assays from different parts of the CpG islands or from
opposing strands were included and the data was pooled
for statistical analysis.
We collected 5076 data points for 24 markers from
213 cores, 2991 data points from 125 control cores and
2085 from 88 case cores. For the control cores, 2803 out
of 2991 (93.7%) yielded no detectable amplification (no
rise in fluorescence level above background). For the can-
cer cases, 1263 reactions out of 2085 yielded no amplifica-
tion, 866 from 49 benign/abnormal cores (73.6%) and 397
from 39 cancer cores (42.4%).Marker characteristics in patients with elevated PSA
The estimated clinical sensitivity and specificity for the
presence (>0 methylation level) of each marker were
computed using cancerous cores from cases and the
core with the highest number of methylated markers
for controls (Table 2). We discarded the data for the
remaining control cores to avoid biasing the specificity
estimates by representing each control twice. We chose
the most methylated core because it represents the high-
est level of methylation available for the individual. The
observed sensitivity for the 24 markers ranged between
11 and 97%, while the specificity ranged between 66 and
100% with the majority of markers exceeding 90%. Over-
all, we observed low levels of methylation in cores
derived from non-cancerous prostates. The sensitivities
and specificities reported here were for the assays that
we chose. For some markers like GSTP1 and APC, we
tested multiple primer-probe combinations before select-
ing the best performing assay for FFPE biopsy DNA. For
other markers like ARHGEF10 and KLK10, we only tested
a single probe. The sensitivities and specificities of some
markers could be further improved by testing different
primers/probe combinations or further optimizing the bi-
sulfite conditions.Methylation is cumulative in cancer cores
Giving equal weight to all markers, we estimated the
sensitivity and specificity associated with the total num-
ber of positive markers (Table 2) again using the cancer
cores from cancer cases and only the most methylated
core from controls. The majority of cancer cores weremethylated at 9 or more markers out of the 24 tested, a
level of methylation that was not observed in controls.
Table 3 presents the best 1, 2, and 3 marker predictive
models observed in the sample as estimated using logis-
tic regression with an indicator of methylation (>0) or a
level of methylation for each marker included as covari-
ates. We split the data into 2 sets, a training set and a
test set. Results depict the cross-validated area under the
ROC curve (AUC) on the training data and the observed
AUC on test data not used in model building. Models
involving KIFC2 and ADCY4 tended to have high out of
sample diagnostic capability, with the AUC in the test
data ranging from 0.91 including only ADCY4 to 0.98
when also including KIFC2. Models which included the
actual level of methylation were also considered and
demonstrated similar results.
Figure 1A shows the receiver operating characteristics
(ROC) curves based on the total number of methylated
markers and their average level of methylation for 37
cancer cores and 67 controls. As in Table 2, we used the
most methylated core from controls. Using 5 positive
markers out of 24 to define a cancer case yields an
AUC = 0.998. Figure 2A shows the ROC curves using 5
markers commonly methylated in benign cores from
cases that could potentially be used for a diagnostic test
on negative first biopsies (HOXB5, HOXB5 plus RASSF5,
HOXB5 plus RASSF5 and ADCY4, HOXB5 plus RASSF5,
ADCY4 and SOCS3, HOXB5 plus RASSF5, ADCY4,
SOCS3 and RASSF1). The AUCs ranged from 0.848 for
HOXB5 to 0.993 when all 5 markers are combined.
Methylation of abnormal cores
Forty seven abnormal cores harboring HGPIN or ASAP
were available for this study, 20 from controls and 27
from cases, including 14 cores from additional cancer
cases which were not included in the primary statistical
analysis because we were unable to obtain tissues from
the corresponding cancer cores. As possible precursors
to cancer [35-38], we expected the abnormal cores to ex-
hibit a methylation profile that falls between benign and
cancer cores. To determine if methylation is elevated in
abnormal cores, we first compared, using the two-
sample t-test, the number of methylated markers in ab-
normal and benign cores from controls and found no
significant difference between the two means (data not
shown). Repeating the analysis using abnormal cores
from cases and controls we found a mean difference of
2.69 (95% CI: 1.63, 3.74; p < 0.001) with abnormal cores
from cases averaging 4.36 methylated markers out of 24.
We then compared the methylation of abnormal and be-
nign cores from cancer cases and found higher levels of
methylation in the benign cores (mean in benign cores:
6.25, n = 36; mean in abnormal cores: 4.36 n = 27; differ-
ence in means =1.89, 95% CI: 0.24-3.54, p = 0.025). For
Table 2 Sensitivities and specificities for individual markers and combination of markers
Cancer cores Control cores Non cancer cores from cases
Marker No. Pos/No. cases Sensitivity 95% CI No. Neg/No. controls Specificity 95% CI No. Pos/No. cases Sensitivity 95% CI
CYBA 22/37 0.59 (0.44, 0.75) 64/67 0.96 (0.91, 1.00) 5/37 0.14 (0.02, 0.25)
HOXB5 31/37 0.84 (0.72, 0.96) 56/67 0.84 (0.75, 0.92) 24/36 0.67 (0.51, 0.82)
RASSF1 33/37 0.89 (0.79, 0.99) 55/67 0.82 (0.73, 0.91) 16/37 0.43 (0.27, 0.59)
SOCS3 27/37 0.73 (0.59, 0.87) 61/67 0.91 (0.84, 0.98) 17/36 0.47 (0.31, 0.64)
GRASP 22/37 0.59 (0.44, 0.75) 64/67 0.96 (0.91, 1.00) 1/37 0.03 (0.00, 0.08)
HAPLN3 27/37 0.73 (0.59, 0.87) 63/67 0.94 (0.88, 1.00) 11/37 0.30 (0.15, 0.44)
SLC16A5 11/37 0.30 (0.15, 0.44) 64/67 0.96 (0.91, 1.00) 2/37 0.05 (0.00, 0.13)
HOXD9 34/37 0.92 (0.83, 1.01) 43/65 0.66 (0.55, 0.78) 29/36 0.81 (0.68, 0.93)
ARHGEF10 8/37 0.22 (0.08, 0.35) 62/67 0.93 (0.86, 0.99) 7/37 0.19 (0.06, 0.32)
KLK10 14/37 0.38 (0.22, 0.53) 67/67 1.00 ? 1/37 0.03 (0.00, 0.08)
GSTP1 25/36 0.69 (0.54, 0.84) 64/67 0.96 (0.91, 1.00) 10/37 0.27 (0.13, 0.41)
RASSF5 28/37 0.76 (0.62, 0.90) 61/67 0.91 (0.84, 0.98) 21/37 0.57 (0.41, 0.73)
MOXD1 12/37 0.32 (0.17, 0.48) 61/67 0.91 (0.84, 0.98) 6/37 0.16 (0.04, 0.28)
RARB 25/37 0.68 (0.52, 0.83) 64/67 0.96 (0.91, 1.00) 4/37 0.11 (0.01, 0.21)
GPX7b 16/37 0.43 (0.27, 0.59) 64/67 0.96 (0.91, 1.00) 5/37 0.14 (0.02, 0.25)
APC 27/36 0.75 (0.61, 0.89) 61/67 0.91 (0.84, 0.98) 12/35 0.34 (0.19, 0.50)
GFRA2 13/36 0.36 (0.20, 0.52) 64/67 0.96 (0.91, 1.00) 5/35 0.14 (0.03, 0.26)
LOXL2 11/36 0.31 (0.16, 0.46) 65/67 0.97 (0.93, 1.00) 5/35 0.14 (0.03, 0.26)
NEUROG3 18/36 0.50 (0.34, 0.66) 64/67 0.96 (0.91, 1.00) 6/35 0.17 (0.05, 0.30)
PTGS2 4/36 0.11 (0.01, 0.21) 65/67 0.97 (0.93, 1.00) 10/35 0.29 (0.14, 0.44)
ADCY4 36/37 0.97 (0.92, 1.03) 56/67 0.84 (0.75, 0.92) 20/37 0.54 (0.38, 0.70)
CXCL14 27/37 0.73 (0.59, 0.87) 63/67 0.94 (0.88, 1.00) 10/37 0.27 (0.13, 0.41)
HEMK1 15/37 0.41 (0.25, 0.56) 60/67 0.90 (0.82, 0.97) 2/37 0.05 (0.00, 0.13)
KIFC2 22/37 0.59 (0.44, 0.75) 67/67 1.00 ? 8/37 0.22 (0.08, 0.35)
3 of 24 37/37 1.00 ? 46/67 0.69 (0.58, 0.80) 31/37 0.84 (0.72, 0.96)
4 of 24 37/37 1.00 ? 56/67 0.84 (0.75, 0.92) 23/37 0.62 (0.47, 0.78)
5 of 24 37/37 1.00 ? 65/67 0.97 (0.93, 1.01) 23/37 0.62 (0.47, 0.78)
6 of 24 36/37 0.97 (0.92, 1.03) 66/67 0.99 (0.96, 1.01) 19/37 0.51 (0.35, 0.67)
7 of 24 36/37 0.97 (0.92, 1.03) 66/67 0.99 (0.96, 1.01) 18/37 0.49 (0.33, 0.65)
8 of 24 36/37 0.97 (0.92, 1.03) 67/67 1.00 ? 15/37 0.41 (0.25, 0.56)
9 of 24 35/37 0.95 (0.87, 1.02) 67/67 1.00 ? 11/37 0.30 (0.15, 0.44)
















Table 2 Sensitivities and specificities for individual markers and combination of markers (Continued)
11 of 24 27/37 0.73 (0.59, 0.87) 67/67 1.00 ? 5/37 0.14 (0.02, 0.25)
12 of 24 25/37 0.68 (0.52, 0.83) 67/67 1.00 ? 5/37 0.14 (0.02, 0.25)
13 of 24 20/37 0.54 (0.38, 0.70) 67/67 1.00 ? 3/37 0.08 (0.00, 0.17)
14 of 24 17/37 0.46 (0.30, 0.62) 67/67 1.00 ? 2/37 0.05 (0.00, 0.13)
15 of 24 15/37 0.41 (0.25, 0.56) 67/67 1.00 ? 1/37 0.03 (0.00, 0.08)
16 of 24 14/37 0.38 (0.22, 0.53) 67/67 1.00 ? 0/37 0.00 ?
17 of 24 11/37 0.30 (0.15, 0.44) 67/67 1.00 ? 0/37 0.00 ?
18 of 24 7/37 0.19 (0.06, 0.32) 67/67 1.00 ? 0/37 0.00 ?
19 of 24 7/37 0.19 (0.06, 0.32) 67/67 1.00 ? 0/37 0.00 ?
20 of 24 3/37 0.08 (0.00, 0.17) 67/67 1.00 ? 0/37 0.00 ?
Shows the estimated sensitivity and specificity associated with each marker (where a marker test is defined as the presence (>0 concentration) or absence (0 concentration) of the particular marker). The column
preceding sensitivity yields the number of ? positive tests ? and the number of ? true cases ? . Similarly, the column preceding specificity yields the number of ? negative tests ? and the number of ? true controls ? . Similarly
for the non-cancer cores from cases, the estimated sensitivity associated with each marker and the sensitivity associated with the total number of markers were calculated using the non-CA core with the highest
















Table 3 AUCs for training and test data











Model Area under ROC using
training data






1 Covariate models 1 Covariate models
HOXD9 0.82 0.74 RASSF5 0.84 0.88
CXCL14 0.82 0.86 HOXD9 0.88 0.92
APC 0.87 0.76 APC 0.88 0.77
RASSF1 0.87 0.83 RASSF1 0.91 0.91
ADCY4 0.9 0.91 ADCY4 0.96 0.98
2 Covariate models 2 Covariate models
ADCY4 + KIFC2 0.97 0.97 ADCY4 + LOXL2 0.98 0.98
RASSF1 + ADCY4 0.96 0.95 ADCY4 + age 0.98 0.98
APC + ADCY4 0.96 0.97 ADCY4 + RASSF1 0.99 0.97
RASSF1 + APC 0.97 0.89 ADCY4 + SOCS3 0.98 0.99
RASSF5 + ADCY4 0.96 0.96 ADCY4 + KIFC2 0.99 0.99
3 Covariate models 3 Covariate models
KIFC2 + RASSF5 + HAPLN3 0.99 0.97 KIFC2 + CXCL14 + GSTP1 0.99 0.94
HOXB5 + APC + RASSF1 0.99 0.98 KIFC2 + ADCY4 + PTGS2 0.99 0.99
ADCY4 + KIFC2 + HAPLN3 0.99 0.98 CYBA + ADCY4 + KIFC2 0.99 0.99
APC + RASSF5 + CXCL14 0.99 0.98 KIFC2 + ADCY4 + CXCL14 1.00 0.99
KIFC2 + RASSF5 + CXCL14 0.99 0.98 SOCS3 + APC + RARB 1.00 0.94
Shows the area under the ROC based upon training data and test data using varying degrees of model complexity. Models consider a yes/no indicator for
methylation (>0) of each individual marker or use the level of methylation as a covariate.
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lation of abnormal cores from cases was not higher than
that of the corresponding benign cores.
Elevated methylation of normal epithelium in cancerous
prostate
The non-cancer cores from cases (CCNC) were randomly
chosen by the pathologist as histologically benign or abnor-
mal. Since we were only analyzing one CCNC core from
most cancer cases, we did not expect a significant differ-
ence in the methylation of benign cores between cases and
controls. However, we found elevated methylation levels in
over half of the 49 CCNC cores analyzed. The mean num-
ber of methylated markers in control cores was 1.5 (SD:
1.44, range: 0 to 7, n = 125 cores), 5.9 for CCNC cores (SD:
3.7, range: 0 to 15, n = 49 cores), and 13.66 for cancer cores
(SD: 4.19, range: 5 to 22, n = 39 cores). Over 60% of the
CCNC cores were methylated at 5 or more markers while
only 3% of the control cores exhibited the same level of
methylation. CCNC cores had on average 4.39 more meth-
ylated markers than control cores (95% CI: 3.06, 5.83; p <
0.001) despite being histologically equivalent.
CCNC cores were also less methylated than the cancer
cores even though the number of methylated markersoverlapped considerably between the two. Cancer cores
had on average, 7.76 more methylated markers than
CCNC cores (95% CI: 5.43, 9.22; p < 0.001). Figure 3
shows the within subject mean difference in methylation
levels for individual markers observed in cancerous
cores when compared to benign cores among cases
(N = 37). As can be seen, the observed methylation levels
were consistently higher among cancerous cores when
compared to CCNC cores for the majority of markers.
Only PTGS2 which codes for the cyclooxygenase 2 (COX2)
enzyme showed higher methylation levels in CCNC cores
(p < 0.065).
We repeated the statistical analysis to estimate the
clinical sensitivity and specificity for individual markers
using only the CCNC cores from cases (excluding all
cancer cores). The results are shown in Table 2. Using
the methylation of any 5 out of 24 markers in CCNC
cores to define a cancer case identified 62% of cases
(Table 2). The receiver operating characteristic (ROC)
curve shows AUCs up to 0.802 for CCNC cores when
the total number of methylated markers and their aver-
age level of methylation were considered (Figure 1B).
The positive predictive value (PPV) for the CCNC
cores was 89.9% (95% CI: 68.9-98.4) and the negative
Figure 1 Receiver operating characteristics (ROC) curves based on the number of methylated markers and their methylation levels
generated with the data used to estimate the sensitivity and specificity in Table 2. (A) shows the ROC curves obtained when the
methylation data for the cancer cores and the methylation data of the most methylated core from controls were used. (B) shows the ROC curves
when the data for the cancer cores is replaced with the methylation of the CCNC core for each cancer patient. In cases where more than one
CCNC core was available, the most methylated core was selected for analysis. Using 5 positive markers out of 24 to identify a cancer case yielded
AUCs of 0.998 and 0.802 for cancer and CCNC cores, respectively.
Figure 2 Examples of receiver operating characteristics (ROC) curves obtained with markers that were commonly methylated in CCNC
cores. The data is shown for HOXB5, and then HOXB5 combined sequentially with up to 4 markers as shown in the list above. (A) shows the
ROC curve obtained when the methylation data for the cancer cores and the methylation data of the most methylated core from controls were
used. (B) shows the ROC curve when the data for the cancer cores is replaced with the methylation of the CCNC core for each cancer patient.
In cases where more than one CCNC core was available, the most methylated core was selected for analysis.
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with a p < 0.0001 when a cancer case is defined by the
methylation at 5 out of 24 markers. Individual markers
like RASSF5 and ADCY4 also performed well in this test
but not as well as combining the methylation content of
multiple markers. Repeating the ROC curve analysis
with 5 markers commonly methylated in benign cores
yields an AUC of 0.781 for HOXB5 to an AUC of 0.864
when all 5 markers (HOXB5, RASSF5, ADCY4, SOCS3,
and RASSF1) are combined (Figure 2B).
Effect of patient and core age on level of methylation
We were not able to obtain sufficient cancer cores from
older cases and had to include cores that were processed
more recently to obtain the 37 cases. While we expected
decreased detection of methylation in older cores, this
was not observed among either cases or controls.
Among cases, it was estimated that a one year increase
in the age of the core is associated with an average de-
crease of 0.64 in the number of methylated markers
(95% CI: −1.47, 0.19; p = 0.127) which is not statistically
significant.
We also expected an increase in methylation levels
in cores obtained from older patients. However, no
significant association between patient age and the
total number of methylated markers was observed in
either cases or controls. Among cases, it was esti-
mated that a one year increase in age is associated
with an average increase of 0.06 in the number ofFigure 3 Paired tests of mean methylation levels between cancerousmethylated markers (95% CI: −0.13, 0.24; p = 0.537).
Similarly among controls, it was estimated that a one
year increase in age is associated with an average in-
crease of 0.03 in the number of methylated markers
(95% CI: −0.01, 0.07; p = 0.537).Effects of tumor volume and Gleason score on density of
methylation
The volume of cancer was less than 20% in 24 cores and
greater than 30% in 15 cores. Twenty one cancer cores
had a Gleason score of 6 or lower and 17 had a Gleason
score of 7 or higher. For most cores, the cancer cells did
not contribute enough DNA to be solely responsible for
the methylation detected with these markers. We expect
that the epigenetic field which extends beyond patho-
logically defined cancer contributed significantly to the
methylation pattern. We also did not see any correlation
between the methylation density and the Gleason score
of the core analyzed (data not shown). However, we ana-
lyzed a relatively small number of cores with a wide range
of tumor volumes using only 24 markers. Correlations be-
tween methylation density, tumor grade and volume are
best done with properly matched cores to avoid errors in-
troduced by the variable number of cancer cells. If the
trend we observed continues in larger studies and with
additional markers, methylation may become an add-
itional variable independent of pathology that can be used
to stratify patients.and non-cancerous cores within the same case (N = 37).
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Epigenetic field effects have previously been reported in
prostate cancer. Truong et al. [24] detected DNA methy-
lation in benign tissues distant from tumors while
Stewart et al. [28] showed that the methylation can be
used to reduce the number of unnecessary repeat biop-
sies. Our study also supports the presence of an epigen-
etic field effect that is not in direct proximity to cancer
foci. The non-cancer cores we analyzed were randomly
chosen by the pathologist and were not selected from
close proximity to known cancer cores. While we cannot
rule out that all methylation positive CCNC cores were
derived from near cancer lesions, this possibility is
highly unlikely since the majority of cores were from re-
peat biopsies. The likelihood that the benign cores har-
bored small cancer foci that were not detected during
three pathological reviews is also unlikely because 10 to
25% of the cells have to be methylated in order for most
markers to be detected using our assays. It is more likely
that the markers are identifying precancerous or cancer-
ous lesions that aren ? t yet pathologically identifiable.
Our data supports the presence of multiple molecularly
abnormal but histologically normal lesions in cancerous
prostates which are not present or present to a signifi-
cantly lesser extent in non-cancerous prostates. They
may contribute to the multifocal nature of prostate
cancer.
Abnormal cores from cancer cases did not exhibit
higher methylation levels than the benign cores for the
24 markers analyzed. Overall, the observed methylation
does not support a role for abnormal cores as precursors
to cancer even though we cannot rule out that the
amount of DNA contributed by the abnormal cells was
below the limit of detection. It is highly possible that the
methylation of the abnormal cores was similar to the
methylation of benign cores because the benign cells
present in abnormal cores contributed the methylation
pattern and the presence of histological aberrations was
a coincidental occurrence. It is also possible that the epi-
genetic signature of abnormal cores differs significantly
from cancer cores and could not be detected using can-
cer specific markers.
We selected a 24 marker panel for this study because
we were expecting significant overlap in methylation
levels between cancer cases and controls as previously
reported [24-28]. We intended to identify the best per-
forming markers for further development. However, this
study showed that there is minimal overall methylation
in controls. Methylation accumulated only in cancerous
prostates which supports the involvement of all selected
markers in the transformation process. ROC curve ana-
lysis (Figures 1b and 2b) supports the selection of a
limited number of markers commonly methylated in
CCNC cores for the development of an epigenetic testaimed at eliminating unnecessary repeat biopsies. HOXB5,
RASSF5, ADCY4, SOCS3, and RASSF1 (Figure 2b) yielded
better AUCs than all 24 markers combined (Figure 1b).
We were able to identify 62% of cancer cases based on
the methylation pattern of a single randomly chosen
CCNC core which raises the question of how wide-
spread the epigenetic field effect is in prostate cancer. It
is difficult to estimate the number of benign cores that
are methylated in cancerous prostates from our study
because we analyzed an average of 1.3 benign cores per
case from patients undergoing repeat biopsies. However,
we anticipate that the number of positive cores will fol-
low a normal distribution heavily skewed towards zero
in non-cancerous prostates and centering around 5 or 6
cores in cancerous prostates. We also anticipate that the
number of methylated markers per core will follow a
normal distribution. The combination of the number of
methylated markers and cores can be used to map all
abnormal areas over the entire gland and convert the
methylation map into risk scores to classify men based
on the likelihood of a positive diagnosis.
The number of methylated markers in CCNC cores
ranged between 0 and 15 and overlapped considerably
with cancer cores. In some cases, the CCNC core was
more methylated than the cancer core. Some markers
like HOXB5, RASSF5, ADCY4, SOCS3, and RASSF1 were
frequently methylated in CCNC cores and may represent
early epigenetic events in tumorigenesis. Others like
GRASP, HEMK1, RARB and SLC16A5 were methylated
mostly in histologically detectable cancer and may repre-
sent later events. The differential methylation of CCNC
and cancer cores may identify critical genes and path-
ways that are required for the development of histologi-
cally visible cancer. It may also reflect the order of
acquisition of methylation events and help define a mo-
lecular clock for PCA.
Epigenetic mapping of the prostate gland may also be
useful in patients with low risk disease who choose a
more conservative treatment approach. Over one third
of men under active surveillance for low grade prostate
cancer are upgraded within 5 years because of disease
progression [39,40]. Mapping of DNA methylation in be-
nign epithelium may help identify men who are at higher
risk for disease progression at the time of first biopsy.
For this purpose, a larger panel of markers may be
needed that includes markers preferentially methylated
in cancer cores in addition to markers commonly methyl-
ated in CCNC cores. We were able to detect methylation
in several patients with negative biopsies up to 4 years
prior to a cancer diagnosis (data not shown) which sug-
gests that the epigenetic aberrations are present at least
4 years prior to a positive biopsy. The ability to accurately
map in biopsy cores the number of abnormal fields and
the extent of their methylation may help identify patients
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active surveillance.
To date, PCA screening and early clinical intervention
while prostate cancer is organ confined haven? t led to a
significant reduction in mortality [41,42]. Epigenetic ab-
errations can be detected prior to the development of
histologically visible cancer. This may allow for earlier
clinical intervention in men at high risk for aggressive
disease. It may also improve the timing and selection of
treatment for men with slower growing cancers reducing
overtreatment of cancers that are clinically insignificant.
PTGS2 was the only marker out of the 24 analyzed
that was more frequently methylated in CCNC than in
cancer cores. The PTGS2 gene codes for the COX2
enzyme which is the target of inhibition by aspirin.
Epidemiological studies have shown that long term
aspirin use is potentially associated with a modest
reduction in prostate cancer risk [43,44]. The inactiva-
tion of the PTGS2 promoter may slow the growth of
precancerous lesions and reduce the likelihood of pro-
gression to pathologically detectable cancer. CCNC
cores may harbor additional methylation that reduces
the growth potential of abnormal cells. There may be
value in mapping epigenetic events that accumulate
preferentially in CCNC cores to identify pathways that
can be targeted for prostate cancer prevention or
treatment.
The MATLOC study analyzed the CpG islands associ-
ated with GSTP1, APC, and RASSF1 in benign biopsy
cores from 498 patients undergoing repeat biopsies [28].
The 3 marker combination yielded 68% sensitivity and
64% specificity based on the methylation of 10 or more
biopsy cores. In our study, these 3 markers yielded 48%
sensitivity, 89% specificity and an AUC of 0.731 based
on the analysis of a single CCNC core. Direct compari-
son between the 2 studies is not straightforward because
of the difference in assay methodology, patient popula-
tion, and number of cores analyzed. However, based on
the data collected from all 125 benign cores from con-
trols, we expect the specificity of these 3 markers to be
significantly higher than the 64% reported by MATLOC.
The higher specificity observed in our study is likely due
to the bisulfite conversion conditions which were tai-
lored for each marker, and were different for RASSF1
than for APC and GSTP1. The majority of cases in the
MATLOC study showed methylation at 2 cores or less.
Given that we identified 62% of cases from the methyla-
tion of a single core, we expect the average number of
positive cores per case to be significantly higher. Add-
itional studies on larger cohorts are needed to better de-
termine the performance of these 3 markers and the rest
of the markers presented here.
Several studies have associated field effects in prostate
with the likelihood of higher grade disease. Makarovet al. [19] showed that the levels of proPSA in tumor ad-
jacent tissues at the time of biopsy are associated with
the need for further treatment in patients enrolled in ex-
pectant management for PCA. Veltri et al. [45] showed
that the nuclear structure information of benign tumor-
associated tissues can help predict the likelihood of
metastatic progression. Could the epigenetic aberrations
in a cancerous prostate also help determine the likeli-
hood of clinically significant disease at the time of diagno-
sis? Furthermore, do aberrant epigenetic fields correlate or
even contribute to cancer metastasis? The first question
can easily be answered by correlating the methylation of
prostatectomy specimens with clinical outcomes. The sec-
ond is more difficult because metastatic tissue samples are
difficult to obtain. However, circulating metastatic cells
and cell free DNA may be an acceptable substitute par-
ticularly as improved molecular methods require signifi-
cantly smaller amounts of starting material.
The extensive methylation in CCNC cores raises many
important questions that could help elucidate the eti-
ology of prostate cancer. If the differential methylation
between controls and cases is validated in larger studies,
it may point to an infectious agent underlying the initi-
ation of prostatic carcinogenesis. Several studies have
linked subtypes of Propionibacterium acnes to prostate in-
flammation and suggested a potential role for P. acnes as a
carcinogenic infectious agent [46-48]. Future prospective
studies evaluating DNA methylation could also investigate
if P. acnes co-localizes with DNA methylation in cancer-
ous prostates.
Approximately 50% of men with a first negative biopsy
will continue to have elevated PSA on subsequent
screening [49]. If half elect to undergo additional biop-
sies at an average cost of $3,172 [50], the repeat biopsy
cost will exceed $1 billion per year. To be widely
adopted, a diagnostic test to eliminate unnecessary biop-
sies needs to balance the clinical utility with the cost of
screening. A diagnostic test that costs as much as a
prostate biopsy will not be readily adopted because it in-
creases diagnostic costs as positive molecular findings
will trigger a repeat biopsy for 30% of patients or more.
We anticipate that a diagnostic test for patients in
need of a repeat biopsy will require the analysis of 5 to
10 markers on all available cores for optimal predictive
power. For each biopsy, twelve or more cores will be an-
alyzed. Each additional marker will significantly impact
the cost and the complexity of the detection assays. It
would be cost effective to minimize the number of as-
says by selecting the most informative and the most ana-
lytically robust markers that can be amplified in a single
multiplex. However, this study clearly demonstrates the
impact of combining the information from multiple
markers. There is significant predictive power in the num-
ber of methylated cores and the number of methylated
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Further studies of these and additional markers are needed
to identify the optimal marker panel that would maximize
clinical value while minimizing screening costs. If the
methylation of first negative biopsies can be analyzed for
about $1,000, an epigenetic test could reduce the cost of
continued PCA screening by over 40% eliminating up to
70% of repeat biopsies.
Epigenetic field effects have been documented in many
cancers [51]. Their role in tumorigenesis is not yet well
understood. The results of this study suggest that more
than 24 markers will be needed to understand the con-
tribution of aberrant fields to the initiation and progres-
sion of cancer. Our ability to detect them in pathologically
benign epithelium with improved analytical accuracy
could have a profound impact on cancer diagnostics, treat-
ment selection, and patient management.
Conclusion
In this study, we presented a panel of 24 markers cap-
able of differentiating between prostate cancer and
benign tissues with greater than 97% sensitivity and spe-
cificity. To the best of our knowledge, this is the first
study to integrate the methylation information from 24
markers in prostate biopsy tissues and show significant
differences in the methylation of benign cores from
PCA patients and controls. This study supports the de-
velopment of a biopsy-based epigenetic test to reduce
the cost of continued screening for PCA. Our data sug-
gests that 5 to 10 markers will be required to achieve
optimal predictive power. The detection and quantita-
tion of epigenetic fields may have additional applications
in identifying prostate cancer patients who are likely
candidates for active surveillance or patients who are at
higher risk for aggressive cancer and progression.
Materials and methods
Please see the Additional file 1 for details on marker se-
lection and assay optimization.
Biopsy tissues
Formalin-fixed paraffin-embedded biopsy tissues (FFPE)
from 100 patients were provided by Dr. Daniel Murtagh
(Promedica Genitourinary Surgeons, Toledo OH) under
an IRB protocol approved by Western Institutional Review
Board (WIRB, study #1123188, Puyallup, WA). The tissue
samples were previously processed as part of routine care
in a single clinic in Ohio. An additional 4 cancer cases
were provided by StrataDX (Lexington, MA). All patients
were deidentified so only the referring physician and path-
ologist knew their identity. Biopsy cores were obtained
from 37 cancers and 67 controls. For each case, we ob-
tained on average 2 cores. For the control cases, either
both cores were benign or one of the cores harboredabnormalities such as high grade intraepithelial neoplasia
(HGPIN) or atypical small acinar proliferation (ASAP).
For the cancer cases, one of the cores was cancer or im-
mediately adjacent to cancer (for 1 case). For 2 cases, the
cancer core contained less than 1% cancer by volume.
Additional cores from cancer cases were benign or abnor-
mal. We analyzed 125 cores from control cases and 88
cores from cancer cases. For each core, we obtained 5
unstained 8 micron sections for DNA extraction. The
laboratory personnel were blinded to the pathological
diagnosis until after the marker data was collected.
Twenty abnormal cores from controls and 13 from cases
harbored pathological abnormalities such as HGPIN or
ASAP. An additional 14 abnormal cores were available
from first negative biopsies from cancer patients with
follow-up time to a positive diagnosis ranging between 2
and 46 months. We were unable to obtain the positive bi-
opsy for these 14 cases. Their data was included only in
the analysis of methylation of abnormal cores.
Statistical methods
Patient characteristics were summarized via the arith-
metic mean and standard deviation for continuous char-
acteristics, and frequency and percentage for categorical
characteristics. Within-subject differences in mean methy-
lation levels between cancerous and non-cancerous core
samples were tested with the paired t test, while mean dif-
ferences in methylation levels of non-cancerous cores
among cases were compared to controls using the two-
sample t-test with unequal variances. The associations be-
tween patient and core sample age with methylation level
were quantified using linear regression stratified by patient
disease status. Sensitivity and specificity associated with
the presence of individual markers, and the total sum of
positive markers, were computed using the observed pro-
portion of individuals with positive markers conditional
upon true disease status. Corresponding 95% confidence
intervals for sensitivity and specificity were computed
using the normal approximation to the binomial distribu-
tion with continuity correction. Multiple logistic regres-
sions were used to estimate diagnostic risk scores based
upon multiple markers. To develop multiple marker risk
scores, the data were randomly divided into two parts.
The first part was used for model training and assessment
(two thirds of the available data; 44 controls and 24 cases),
and the second was used for model testing (one third of
available data; 23 controls and 13 cases). The test data set
was not used in model fitting and selection. A best subsets
procedure was used to identify the top diagnostic models
using data from multiple markers. Specifically, we consid-
ered all possible one, two, and three marker combinations.
Top performing models were selected based upon the area
under the receiver operating characteristic curve (AUC)
that was observed using the risk score defined by the
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considered covariates. Four-fold cross validation estimates
of AUC were used to rank models for their predictive abil-
ity while avoiding over-fitting at the training stage. The
top performing models (those attaining the highest AUC
in the training data) where then applied to the test data.
Parameter estimates were not re-estimated using the test
data, but were maintained from the training data in order
to provide an honest assessment of out-of-sample diag-
nostic performance. After applying each model to the test
data, risk scores were generated and the AUC for the test
sample was computed. AUC was computed using the
ROCR package (http://cran.r-project.org/web/packages/
ROCR) for the R statistical programming language
(Ver 3.0). Models including only a binary indicator
for methylation level (>0 vs 0) as well as the methy-
lation level were considered. To calculate the mean
difference in the number of methylated markers be-
tween 2 groups of biopsy cores, we used the two-
sample t-test function.
Additional file
Additional file 1: Contains the methods used to generate the
marker data. It shows the marker selection, the chromosomal location
of CpG islands, and a list of the primers and conditions used for MS-qPCR
assays. It also describes the optimization protocol used for the bisulfite
conversion [52-57].
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